INDIGO Biosciences, Inc. provides life science solutions, specializing in in vitro cell-based reporter assay systems and screening services for pharmaceutical and research markets. Headquartered in State College, Pennsylvania, the company supports environmental, toxicological, and drug discovery testing.
Subscribe to see INDIGO Biosciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
INDIGO Biosciences is a life sciences company headquartered in State College, United States. Its most recent funding round, Series B, raised $500,000 in August 2016. Xcout tracks 6 named people at INDIGO Biosciences, including Fred Marroni (President & Chief Executive Officer).
As of 20 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $500,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of INDIGO Biosciences's closest competitors — see the full list of competitors and alternatives →
InSphero provides 3D in vitro cell culture models, microplates, organ-on-a-chip platforms, and related services for drug discovery and safety testing. The company serves pharmaceutical, biotechnology, and research organizations seeking non-animal testing alternatives to evaluate drug efficacy, liver safety, oncology, and other complex diseases.
Aurora Bio, Inc. provides life science research products and services, including fluorescence assay kits, recombinant proteins, inhibitor compounds, and protein purification resins. It also offers custom services such as assay development, high-throughput compound library screening, protein expression, and antibody conjugation primarily for researchers in drug discovery.
Promega Corporation provides products, reagents, and technical support for life science research, drug discovery, and clinical diagnostics.
BICO provides lab automation software, instruments, biomaterials, and liquid handling solutions for life science research, drug discovery, and tissue engineering. The company serves pharmaceutical companies, biotechnology firms, and academic institutions by automating laboratory workflows and providing 3D bioprinting and imaging technologies.
Hubrecht Organoid Technology (HUB) develops patented patient-derived organoid technology from healthy and diseased tissues to predict patient responses to treatments. The company functions as a contract research organization (CRO), offering drug discovery services, custom model and assay development, clinical trials in a dish, and licensing programs for pharmaceutical and research applications.
DeepCyte Inc. is an AI-powered biotechnology and toxicology platform headquartered in Wilmington, Delaware. Established in 2025, the company develops advanced computational tools for toxicity assessment and life sciences research.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about INDIGO Biosciences? Suggest a correction · Work at INDIGO Biosciences? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.